Lexeo Therapeutics (LXEO) Operating Expenses (2022 - 2026)

Lexeo Therapeutics has reported Operating Expenses for 5 years, with the latest figure at $22.3 million in Q1 2026.

• Quarterly Operating Expenses fell 33.94% year-over-year to $22.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.8 million (down 15.91% YoY) and the FY2025 annual result came in at $109.3 million, up 3.3% from the prior year.
• Operating Expenses fell to $22.3 million in Q1 2026 per LXEO's latest filing, from $23.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $33.8 million in Q1 2025 and troughed at $14.0 million in Q2 2023.
• A 5-year average of $22.6 million and a median of $22.3 million in 2026 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2026: Operating Expenses jumped 82.86% in 2024, then sank 33.94% in 2026.
• Over 5 years, Operating Expenses stood at $15.2 million in 2022, then slipped by 1.47% to $15.0 million in 2023, then surged by 82.86% to $27.4 million in 2024, then retreated by 15.58% to $23.1 million in 2025, then slipped by 3.39% to $22.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $22.3 million, $23.1 million, and $21.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.